| Document |
Document Title |
|
JP3421338B2 |
A process for the manufacture of vancomycin which does not require preparation of a phosphate intermediate. The process consists of passing a vancomycin broth through a suitable adsorbent, followed by passing the vancomycin through a sec...
|
|
JP2003174875A |
To provide a truncated HCV envelop protein useful for the immunoassay and as a vaccine for treatment/prevention.The truncated HCV glycoprotein selected from the group comprising a glycoprotein that is expressed from the E1 region of HCV ...
|
|
JP3418693B2 |
PURPOSE: To obtain a gluconic acid deriv. useful as a medical polymer material by substituting the whole or part of the structural units of a specific poly-L- lysine polypeptide with ε-D-galactopyranosylgluconamidine-L residues. CONSTIT...
|
|
JP3418762B2 |
The present invention is directed to novel antibiotic A 40926 derivatives characterized by having a carboxy, (C1-C4)alkoxycarbonyl, aminocarbonyl, (C1-C4)alkylaminocarbonyl, di(C1-C4)alkylaminocarbonyl or hydroxymethyl substituent on the...
|
|
JP2003513009A |
Peptide-lipid conjugates are incorporated into liposomes so as to selectively destabilize the liposomes in the vicinity of target peptidase-secreting cells, and hence, to deliver the liposomes to the vicinity of the target cells, or dire...
|
|
JP2003512475A |
The present invention is directed to the sodium salt of formula 5:which may be useful in the treatment of prostate cancer and benign prostatic hyperplasia. Also described are lyophilized formulations that comprise the sodium salt 5 or th...
|
|
JP2003503465A |
Compound of the general formula (I) X(B)m (I) wherein X is an m-valent unit and B are identical or different and denote K-R, wherein K is a bond or is A1-(A2-A3)k-sp, wherein A1 is (CH2)tY(CH2)u, wherein Y is >C-O, >NH, -O-, -S- or a bon...
|
|
JP2003502340A |
Retro-inverso peptides derived from interleukin-3 (IL-3) having between 12 and about 40 amino acids and including the sequence shown in SEQ ID NO: 1. These peptides have the same activity as native IL-3 and also have neurotrophic activit...
|
|
JP3361126B2 |
Phosphoinositolglycan peptides, obtainable by cleavage of adenosine-3%,5%-cyclic monophosphate binding protein, which contain glucosamine, galactose, mannose, inositol, phosphoric acid, ethanolamine and a peptide containing the sequence ...
|
|
JP3357883B2 |
The present invention provides novel cytokine restraining agents, which limit or control the biological activity of cytokines. The invention also provides pharmaceutical compositions comprising a cytokine restraining peptide and methods ...
|
|
JP2002539132A |
The invention relates to a method for producing glyco-conjugates of 20(S)-camptothecin in which a 3-O-methylated beta -L-fucose building block is linked to the 20 hydroxyl group of a camptothecin derivative via thiourea-modified peptide ...
|
|
JP3339888B2 |
Carboxylic acid esters of polar hydrophilic alcohols, of the formula in which R is an unbranched or branched organic radical which contains as polar members between aliphatic or araliphatic hydrocarbon bridges ether oxygens, amine nitrog...
|
|
JP3335634B2 |
Macromolecules are provided that have increased nuclease resistance, increasing binding affinity to a complementary strand, and that activate RNase H enzyme. The macromolecules have the structure PNA-DNA-PNA where the DNA portion is comp...
|
|
JP2002533472A5 |
|
|
JP3324804B2 |
Peptides with insulin-like activity and the formula I where C is a hydrogen atom, amino-acid residue, substituted amino-acid residue or sugar residue, D is an amino-acid residue, phosphoamino-acid residue, sugar residue, covalent bond or...
|
|
JP2002527093A |
The present invention is directed to contulakin-G (which is the native glycosylated peptide), a des-glycosylated contulakin-G (termed Thr10-contulakin-G), and derivatives thereof, to a cDNA clone encoding a precursor of this mature pepti...
|
|
JP3314930B2 |
The present invention relates to novel ester derivatives of antibiotic A 40926 complex and its N-acylaminoglucuronyl aglycone. The compounds of the invention are prepared according to an esterification process involving reaction of an A ...
|
|
JP2002520422A |
Methods for preparing a glycopeptide are disclosed. The methods comprise the steps of selecting a protected glycopeptide of the formula A1-A2-A3-A4-A5-A6-A7, wherein the groups A1 to A7 comprise the heptapeptide structure of naturally oc...
|
|
JP3295431B2 |
Compounds and libraries are labeled with a galactosyl epitope amd then screened in accordance with an assay involving cells having a characteristic of interest. Conveniently, the screening may embody target cells, where the compounds are...
|
|
JP2002517474A |
(57) [Summary] A combinatorial library is disclosed that includes a predetermined collection of nucleoside peptide molecules for suppressing the transfer of sugar from a selected nucleotide donor to a selected receptor by a carbohydrate ...
|
|
JP2002516634A |
The present invention teaches the use of antibodies raised against the Group A mucopeptide for the treatment of septic shock and Rheumatoid Arthritis, and the identification of specific peptides that can be used in such treatments. The i...
|
|
JP3276632B2 |
Tetrapeptides of general formula (I) deriving from dalbaheptide antibiotics wherein: W and Z represent the relative portions of the aglycon of an antibiotic of the dalbaheptide group (aglucodalbaheptides); Y represents a carboxyacid grou...
|
|
JP2002507577A |
The present invention provides novel alpha-O-linked glycoconjugates such as alpha-O-linked glycopeptides, as well as convergent methods for the synthesis thereof. The general preparative approach is exemplified by the synthesis of the mu...
|
|
JP3256236B2 |
Nucleosides and linked nucleosides functionalized to include alkylthiol chemical functionality at ribofuranosyl positions, nucleosidic base positions, or on internucleoside linkages. In certain embodiments, the compounds of the invention...
|
|
JP2001526661A |
The present invention relates to glycoconjugates of 20(S)-camptothecin, in which a 3-O-methylated beta-L-fucose unit is linked to the 20-hydroxyl group of a camptothecin derivative via a thiourea-modified peptide spacer. The invention fu...
|
|
JP2001524944A |
(57) [Summary] The present invention provides a method for relieving a subject's neuropathic pain by administering a neuropathic pain-relieving amount of a prosaposin receptor agonist to the subject. The present invention also provides a...
|
|
JP2001524083A |
The present invention is directed to teicoplanin derivatives of the following general formula: These derivatives are useful as antibiotics for the control of gram-positive bacteria.
|
|
JP2001521386A |
New modified human tumour necrosis factoralpha , TNFalpha , (I) , able to generate, in humans, neutralising antibodies (Ab) to wild-type human TNFalpha (Ia): (a) has >= 1 fragment of TNF substituted by a peptide containing an immunodomin...
|
|
JP2001521527A |
The present invention is directed to deacyl teicoplanin, and to a process for preparing deacyl teicoplanin by reacting teicoplanin with ECB deacylase. Deacyl teicoplanin can be alkylated to produce compounds useful for their antibacteria...
|
|
JP2001520673A |
The invention relates to therapeutic compositions and methods for treating and preventing infection by an immunodeficiency virus, particularly HIV infection, using chemokine proteins, nucleic acids and/or derivatives or analogs thereof.
|
|
JP3223260B2 |
The present invention relates generally to a T cell growth factor. More particularly, the present invention relates to a T cell growth factor which comprises a glycoprotein which supports interleukin 2- and interleukin 4-independent grow...
|
|
JP2001286290A |
To provide a top-cleaved HCV envelop protein useful for the immunoassay and as a vaccine for treatment/prevention. This top-cleaved HCV envelop protein is such as to be selected from a glycoprotein that is expressed from the E1 region of...
|
|
JP3208570B2 |
PURPOSE: To obtain the title substitution product which is useful as a missile drug carrier by replacing a part or the whole of th peptides forming a given polypeptide with specific residues of ω-galactosamyl-L-glutamic acid (or asparti...
|
|
JP3207155B2 |
To obtain a truncated type hepatitis C virus(HCV) envelope protein useful for immunoassay and a therapeutic/prophylactic vaccine. This HCV truncated type glycoprotein is expressed from an envelope protein 1 (E1) region of HCV and is sele...
|
|
JP2001513573A |
The present invention is directed to methods for treating infections caused by Staphylococcus aureus with reduced glycopeptide sensitivity. The invention is preferably practiced with strains of Staphylococcus aureus which are methicillin...
|
|
JP2001220399A |
To obtain a primer capable of being used for synthesizing a glycopeptide or a neoglycopeptide and to provide a method for efficiently producing the glycopeptide or the neoglycopeptide using the primer.This polymeric primer for synthesizi...
|
|
JP2001213891A |
To provide the use of 1,5-D-anhydrofluctose or a sugar chain containing the 1,5-D-anhydrofluctose as a constituting sugar as a sugar donor, especially a sugar donor to an amino compound.The use of 1,5-D-anhydrofluctose or a sugar chain c...
|
|
JP2001509777A |
The present invention provides a method for the preparation of disaccharides, such as glucosaminyl muramic acids peptides and derivatives. The method includes condensing a protected muramic acid ester with a 1-organothio- or 1-fluorogluc...
|
|
JP3169220B2 |
Newly discovered lipoglycopeptide antibiotic A84575 complex, comprising factors A, B, C, D, E, F, G, and H, is produced by submerged aerobic fermentation of a culture selected from Streptosporangeum carneum NRRL 18437, Streptosporangeum ...
|
|
JP2001506232A |
PCT No. PCT/EP97/05089 Sec. 371 Date Mar. 24, 1999 Sec. 102(e) Date Mar. 24, 1999 PCT Filed Sep. 17, 1997 PCT Pub. No. WO98/14468 PCT Pub. Date Apr. 9, 1998The present invention relates to glycoconjugates of camptothecin derivatives in w...
|
|
JP3164844B2 |
PURPOSE: To obtain the subject antagonist for the treatment, etc., of a mammary cancer, prostatic cancer, etc., which has a specific amino acid sequence and has a suppression activity against the formation of lutropin and follitropin of ...
|
|
JP3164463B2 |
PURPOSE: To provide the new peptides which are comprised of variant derivatives of parathyroid hormone and useful as the pharmaceuticals which have parathyroid hormone-like activities and are useful for preventing and treating all bone c...
|
|
JP3162069B2 |
|
|
JP2001503784A |
This invention is concerned with improved processes for reductive alkylation of glycopeptide antibiotics, the improvement residing in employing pyridine.borane as reducing agent.
|
|
JP2001502656A |
PCT No. PCT/EP97/00917 Sec. 371 Date Aug. 28, 1998 Sec. 102(e) Date Aug. 28, 1998 PCT Filed Feb. 26, 1997 PCT Pub. No. WO97/31941 PCT Pub. Date Sep. 4, 1997The compounds of formula (I) cyclo[X11-Z12-X23-X34-Z25-X46]cyclo(2 beta -5 beta )...
|
|
JP2001046098A |
To produce a glycopeptide in which a mucin type sugar chain is bonded in good yield. Galactose and sialic acid are successively bonded to a GalNAc- bonded peptide or simultaneously reacted therewith using a β-galactosidase and a silyltr...
|
|
JP3131222B2 |
Oligonucleotides and other macromolecules are provided that have increased nuclease resistance, substituent groups for increasing binding affinity to complementary strand, and subsequences of 2'-deoxy- erythro- pentofuranosyl nucleotides...
|
|
JP3130565B2 |
PURPOSE: To produce by a specific method a novel saccharide oligopeptide derivative capable of atereo selectively and effectively giving a saccharide oligopeptide useful for the clarification of the receptor structure of lectin for recog...
|
|
JP3126981B2 |
Hexapeptides of formula (I) deriving from aglucoteicoplanin and their salts with acids and bases as well as their inner salts, wherein R is hydrogen or a protecting group of the amino moiety. The products of formula (I), wherein R is hyd...
|
|
JP2001002696A |
To obtain a polymer useful for purpose of diagnosis and other studies or controlling a protein diagnosis in organisms or diagnosis, detection and treatment of other state which is sensitive to antisense therapy.This polymer comprises plu...
|
